Sec Form 3 Filing - LUDVIGSON DAVID @ Boston Therapeutics, Inc. - 2021-06-04

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person LUDVIGSON DAVID 2. Issuer Name and Ticker or Trading Symbol Boston Therapeutics, Inc. [ BTHE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO and President (Last) (First) (Middle) C/O BOSTON THERAPEUTICS, INC., 5900 HOLLIS STREET 3. Date of Earliest Transaction (MM/DD/YY) 06/04/2021 (Street) EMERYVILLE, CA95608 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, $0.0001 par value per share 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series C Preferred Stock ( 1 ) ( 1 ) 06/04/2021 ( 1 ) Common Stock, $0.0001 par value per share 58,316,292 D Warrants ( 2 ) $ 0.0034 06/04/2021 06/04/2026 Common Stock, $0.0001 par value per share 6,503,659 D Restricted Stock Units ( 3 ) $ 0 06/04/2021 06/04/2031 Common Stock, $0.0001 par value per share 181,809,374 D Incentive Stock Options ( 4 ) $ 0.0003 11/30/2012 11/30/2022 Common Stock, $0.0001 par value per share 7,218,039 D Incentive Stock Options ( 4 ) $ 0.0014 03/31/2014 03/31/2024 Common Stock, $0.0001 par value per share 96,742,608 D Incentive Stock Options ( 4 ) $ 0.0014 10/04/2016 10/04/2026 Common Stock, $0.0001 par value per share 14,916,033 D Incentive Stock Options ( 4 ) $ 0.0014 05/31/2017 05/31/2027 Common Stock, $0.0001 par value per share 14,730,691 D Incentive Stock Options ( 4 ) $ 0.0017 02/11/2020 02/11/2030 Common Stock, $0.0001 par value per share 22,096,037 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other LUDVIGSON DAVID C/O BOSTON THERAPEUTICS, INC. 5900 HOLLIS STREET EMERYVILLE, CA95608 X CEO and President Signatures /s/ David Ludvigson 06/30/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of Series C Preferred Stock has a stated value of $1.00 per share and is convertible into shares of common stock at a conversation rate of 6,066.044596 shares of common stock for each share of Series C Preferred Stock. The shares of Series C Preferred Stock are automatically converted upon the filing of an amendment to the Company's certificate of incorporation implementing a reverse stock split. ( 2 )The shares underlying the warrants and the RSU may not be exercised until the implementation of a reverse stock split. ( 3 )RSUs vesting over 2 years ( 4 )Previously issued ISO stock options vested and unvested

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.